Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease

Domestic use of cholinesterase inhibitors huperzine A tablets to double-blind treatment of 28 cases (treatment group and the control group 14 cases, sex, age, duration of no difference in the treatment group and the control group of patients .) Alzheimer (Eercimo) disease at a dose of 200μg, bid; 60d with WMS evaluate the efficacy of treatment, the treatment group before and after treatment were 51.4 ± 14.1 and 61.8 ± 15.9, the control group was 35.6 ± 16.2 and 37.0 ± 11.4 (P0. .005);. two rates were 71.4% and 25.5% respectively (P0.005) In addition, other Intelligence Scale (HDS, MMSE) and the amount of daily life before and after contrast (ADL), the treatment group than the control group significantly improved in the treatment group and no significant side effects in this paper, results suggest that huperzine A tablet on Alzheimer's disease and memory impairment and function effectively improve the lives of patients, and patients taking the tablet easier.